Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection

PLoS Pathogens

Volumn 10, Issue 6, 2014, Pages

  Itoh, Yasushi ^a   Yoshida, Reiko ^b   Shichinohe, Shintaro ^c   Higuchi, Megumi ^b   Ishigaki, Hirohito ^a   Nakayama, Misako ^a   Pham, Van Loi ^a   Ishida, Hideaki ^a   Kitano, Mitsutaka ^a,d   Arikata, Masahiko ^a   Kitagawa, Naoko ^a   Mitsuishi, Yachiyo ^a   Ogasawara, Kazumasa ^a   Tsuchiya, Hideaki ^a   Hiono, Takahiro ^c   Okamatsu, Masatoshi ^c   Sakoda, Yoshihiro ^c   Kida, Hiroshi ^c   Ito, Mutsumi ^e   Quynh Mai, Le ^f   Kawaoka, Yoshihiro ^e,g   Miyamoto, Hiroko ^b   Ishijima, Mari ^b   Igarashi, Manabu ^b   Suzuki, Yasuhiko ^b   Takada, Ayato ^b   more..

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH133; MONOCLONAL ANTIBODY CH226; MONOCLONAL ANTIBODY CH61; MONOCLONAL ANTIBODY M61; PERAMIVIR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; NEUTRALIZING ANTIBODY; SIALIDASE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCAPE BEHAVIOR; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLUENZA VIRUS A H5N1; LUNG PARENCHYMA; MACACA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMONIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; CELL LINE; DOG; DRUG COMBINATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); ISOLATION AND PURIFICATION; LUNG; MACACA FASCICULARIS; MDCK CELL LINE; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PROCEDURES; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CELL LINE; CYCLOPENTANES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; GUANIDINES; IMMUNIZATION, PASSIVE; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H5N1 SUBTYPE; INTERLEUKIN-6; LUNG; MACACA FASCICULARIS; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL LOAD;

EID: 84903458602     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004192     Document Type: Article

References (51)

1. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y, (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56: 152-179.
2. Rohm C, Zhou N, Suss J, Mackenzie J, Webster RG, (1996) Characterization of a novel influenza hemagglutinin, H15: criteria for determination of influenza A subtypes. Virology 217: 508-516.
3. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79: 2814-2822.
4. Li KS, Guan Y, Wang J, Smith GJD, Xu KM, et al. (2004) Genesis of highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430: 209-213.
5. Chen H, Smith GJD, Zhang SY, Qin K, Wang J, Li KS, et al. (2005) H5N1 virus outbreak in migratory waterfowl. Nature 436: 191-192.
6. Ducatez MF, Olinger CM, Owoade AA, De Landtsheer S, Ammerlaan W, et al. (2006) Avian flu: multiple introductions of H5N1 in Nigeria. Nature 442: 37.
7. Smith GJD, Fan XH, Wang J, Li KS, Qin K, et al. (2006) Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci USA 103: 16936-16941.
8. Wang G, Zhan D, Li L, Lei F, Liu B, et al. (2008) H5N1 avian influenza re-emergence of Lake Qinghai: phylogenetic and antigenic analyses of the newly isolated viruses and roles of migratory birds in virus circulation. J Gen Virol 89: 697-702.
9. Kajihara M, Matsuno K, Simulundu E, Muramatsu M, Noyori O, et al. (2011) An H5N1 highly pathogenic avian influenza virus that invaded Japan through waterfowl migration. Jpn J Vet Res 59: 89-100.
10. Sakoda Y, Ito H, Uchida Y, Okamatsu M, Yamamoto N, et al. (2012) Reintroduction of H5N1 highly pathogenic avian influenza virus by migratory water birds, causing poultry outbreaks in the 2010-2011 winter season in Japan. J Gen Virol 93: 541-550.
11. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y, (2008) Human infection with highly pathogenic H5N1 influenza virus. Lancet 371: 1464-1475.
12. WHO. (2013) Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Available: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html. Accessed 14 May 2014.
13. Klenk HD, Garten W, Matrosovich M, (2011) Molecular mechanisms of inter-species transmission and pathogenicity of influenza viruses: lessons from the 2009 pandemic. BioEssays 33: 180-188.
14. Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR, (2013) Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 31: 1553-1559.
15. Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, et al. (2006) Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 193: 796-801.
16. Müller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, et al. (2009) Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 3: e542.
17. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B, (2003) Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 188: 53-56.
18. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, et al. (2004) Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363: 2139-2141.
19. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, et al. (2006) Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 3: e237.
20. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, et al. (2011) A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 3: 105ra103.
21. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, et al. (2012) A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med 4: 146ra107.
22. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, et al. (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109: 5034-5039.
23. Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, et al. (2012) Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 7: e36192.
24. Qiu X, Audet J, Wong G, Pillet S, Bello A, et al. (2012) Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4: 138ra81.
25. Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, et al. (2012) Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 109: 18030-18035.
26. Kreijtz JH, Fouchier RA, Rimmelzwaan GF, (2011) Immune responses to influenza virus infection. Virus Res 162: 19-30.
27. Le QM, Ito M, Muramoto Y, Hoang PV, Vuong CD, et al. (2010) Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam. J Gen Virol 91: 2485-2490.
28. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
29. Pham VL, Nakayama M, Itoh Y, Ishigaki H, Kitano M, et al. (2013) Pathogenicity of pandemic H1N1 influenza A virus in immunocompromised cynomolgus macaques. PLoS One 8: e75910.
30. Kitano M, Itoh Y, Kodama M, Ishigaki H, Nakayama M, et al. (2011) Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother 55: 4961-4970.
31. Daniels PS, Jeffries S, Yates P, Schild GC, Rogers GN, et al. (1987) The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J 6: 1459-1465.
32. Eisen MB, Sabesan S, Skehel JJ, Wiley DC, (1997) Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystallography. Virology 232: 19-31.
33. Russell RJ, Stevens DJ, Haire LF, Gamblin SJ, Skehel JJ, (2006) Avian and human receptor binding by hemagglutinins of influenza A viruses. Glycoconj J 23: 85-92.
34. Ha Y, Stevens DJ, Skehel JJ, Wiley DC, (2001) X-ray structures of H5 avian and H9 swine influenza virus hemagglutinins bound to avian and human receptor analogs. Proc Natl Acad Sci USA 98: 11181-11186.
35. Hatta M, Gao P, Halfmann P, Kawaoka Y, (2001) Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293: 1840-1842.
36. Park CH, Ishinaka M, Takada A, Kida H, Kimura T, et al. (2002) The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in mice. Arch Virol 147: 1425-1436.
37. Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, et al. (2013) Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine. PLoS ONE 8: e82740.
38. Wu C, Lu X, Wang X, Jin T, Cheng X, et al. (2013) Clinical symptoms, immune factors, and molecular characteristics of an adult male in Shenzhen, China infected with influenza virus H5N1. J Med Virol 85: 760-768.
39. Nakajima N, Van Tin N, Sato Y, Thach HN, Katano H, et al. (2013) Pathological study of archival lung tissues from five fatal cases of avian H5N1 influenza in Vietnam. Mod Pathol 26: 357-369.
40. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, et al. (2005) Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection. N Engl J Med 353: 2667-2672.
41. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: Isolation of drug-resistant H5N1 virus. Nature 437: 1108-1108.
42. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, et al. (2010) Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol 91 (Pt 4) (): 949-959.
43. Zhou B, Zhong N, Guan Y, (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357: 1450-1451.
44. Chen Y, Qin K, Wu WL, Li G, Zhang J, et al. (2009) Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 199: 49-58.
45. Oh HL, Akerström S, Shen S, Bereczky S, Karlberg H, et al. (2010) An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 84: 8275-8286.
46. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
47. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, et al. (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7: 126.
48. Maneewatch S, Thanongsaksrikul J, Songserm T, Thueng-In K, Kulkeaw K, et al. (2009) Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1. Antivir Ther 14: 221-230.
49. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
50. van den Brand JM, Haagmans BL, van Riel D, Osterhaus AD, Kuiken T, (2014) The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models. J Comp Pathol (in press).
51. Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, et al. (2009) Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 4: e5672.